CD8A and neoplasm: SKOV‐3 ovarian tumor cells were chosen as the model to study the effect of tumor antigen obtained through HOCL‐oxidation; it induced rapid primary necrosis, enhanced the uptake of ovarian tumor by DCs, and primed autologous tumor‐specific CD4+ and CD8+ T cell responses.[194] In a pilot study of five patients with recurrent ovarian cancer, the immunogenicity, clinical efficacy, and progression‐free survival (PFS) of autologous DCs pulsed with HOCl‐oxidized autologous tumor lysate (OCDC vaccine) were evaluated.